-

Gilead Sciences to Present at Upcoming Investor Conference

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conference:

Morgan Stanley Annual Global Healthcare Conference on Wednesday, September 15 at 12:30pm ET

The live webcast can be accessed at the company’s investors page at investors.gilead.com. The replay will be available for at least 30 days following the presentation.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contacts

Jacquie Ross, Investors
(650) 358-1054

Industry:

Gilead Sciences, Inc.

NASDAQ:GILD
Release Versions
English
$Cashtags
$GILD
Hashtags
#GILD

Contacts

Jacquie Ross, Investors
(650) 358-1054

More News From Gilead Sciences, Inc.

New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention

FOSTER CITY, Calif.--(BUSINESS WIRE)--New Data Show Twice-Yearly Lenacapavir Achieved Nearly Twice the One-Year Persistence of Daily Oral F/TDF in HIV Prevention...

Positive Phase 3 IDEAL Study Results Further Support Livdelzi®’s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi® (seladelpar) achieved the alkaline phosphatase (ALP) normalization composite endpoint defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥ 15% decrease from baseline. ALP is a key marker of disease activity and long-term outcomes in PBC. The...

Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition (December 12–15, 2026). These latest clinical milestones demonstrate transformative progress across Gilead and Kite’s pipeline and portfolio, from new data for the investigational anitocabtagene autoleucel (anito-cel) in relapsed or...
Back to Newsroom